Clinical Trial Update: Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab in patients with persistent, recurrent, or metastatic cervical cancer; results were posted in August 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Adenocarcinoma
• Cervical Adenosquamous Carcinoma
• Cervical Cancer

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2020-08-12